Effect of initial high-efficacy disease modifying therapy in relapsing-remitting MS

BestPractice | Syys 2019 | ECTRIMS 2019 |

Patients with MS are often initially treated with moderately effective disease modifying therapies, and in case of insufficient treatment response therapy is escalated to high efficacy disease modifying therapies. In this MEDtalk Mathias Due Buron present Danish data for difference of disease activity in patients started initially on high efficacy disease modifying therapies compared to similar patients started moderately effective disease modifying therapies.